Gilead Sciences Inc. closed $7.05 short of its 52-week high ($98.90), which the company reached on November 11th.

At 24 months, endocrine therapy appeared to have a more negative effect on HRQOL as measured by the global health status (GHS ...

Kyverna Therapeutics, Inc. (Kyverna), a clinical-stage biopharmaceutical company focused on developing cell therapies for ...

Gilead Sciences (GILD) ended the recent trading session at $91.86, demonstrating a -0.57% swing from the preceding day's closing price. On the other hand, the Dow registered a loss of 0.2%, and the ...

US antivirals major Gilead Sciences announced that Dr Dietmar Berger will join the company on January 2, 2025, as chief ...

Berger specialized in cancer long before joining Genentech, holding oncology global clinical development roles at Amgen and ...

In a report released today, Asthika Goonewardene from Truist Financial assigned a Hold rating to Gilead Sciences (GILD – Research Report). The company’s shares closed yesterday at $92.38. Pick the ...

Sciences announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive ...

Gilead Sciences, Inc. has announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical ...

Equities research analysts at Zacks Research raised their FY2025 earnings per share (EPS) estimates for Gilead Sciences in a ...

Gilead Sciences said a key European regulatory committee recommended expanded approval of its seladelpar treatment for patients with primary biliary cholangitis, a chronic and progressive liver ...

(Reuters) -Gilead Sciences said on Thursday it has appointed Sanofi’s Dietmar Berger as its chief medical officer, replacing ...